XENCOR Reports 50.8% Increase in Revenue for Q2 FY2023

August 21, 2023

☀️Earnings Overview

For the fiscal year ending June 30, 2023, XENCOR ($NASDAQ:XNCR) reported total revenue of USD 45.5 million for its second quarter, up 50.8% from the same quarter in the prior year. Net income for the quarter was USD -22.0 million, an improvement from -34.0 million in the same period last year.


GoodWhale has conducted an analysis of XENCOR‘s fundamentals and has come to the conclusion that the company has an intermediate health score of 4/10 when it comes to its cashflows and debt. This indicates that the company has potential to stay financially stable in the face of economic crisis. According to its Star Chart, XENCOR is strong in asset, medium in growth, profitability and weak in dividend. We classify this type of company as a ‘rhino’, meaning that it has achieved moderate revenue or earnings growth. The type of investor that may be interested in such a company is likely looking for a solid base on which to build. XENCOR’s strength in asset provides an opportunity for investors to look at the potential growth that can occur with the proper expansion plan in place. With the company’s moderate growth rate, investors may be attracted to the promise of potential returns if the business is managed correctly. Furthermore, investors may be looking for a financial cushion from the company’s medium scores in profitability and growth. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • XENCOR_Reports_50.8_Increase_in_Revenue_for_Q2_FY2023″>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Xencor. More…

    Total Revenues Net Income Net Margin
    113.39 -127.52 -139.6%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Xencor. More…

    Operations Investing Financing
    -94.41 74.41 5.3
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Xencor. More…

    Total Assets Total Liabilities Book Value Per Share
    778.12 99.25 11.24
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Xencor are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    17.0% -15.0% -146.7%
    FCF Margin ROE ROA
    -120.2% -15.3% -13.4%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    Xencor‘s competitors include Aptevo Therapeutics Inc, Landos Biopharma Inc, and PDS Biotechnology Corp.

    – Aptevo Therapeutics Inc ($NASDAQ:APVO)

    Aptevo Therapeutics Inc. is a biotechnology company that discovers, develops and commercializes novel, oncology and hematology therapeutics to improve patient care. The company’s products include the anti-CD33 antibody, liso-cel, and inotuzumab ozogamicin. Aptevo Therapeutics Inc. has a market cap of 14.61M as of 2022 and a return on equity of -159.96%. The company’s products are used to treat leukemia, lymphoma and other blood disorders.

    – Landos Biopharma Inc ($NASDAQ:LABP)

    Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with autoimmune diseases. The company’s lead product candidate, BT-11, is a first-in-class, orally-available, small molecule selective inhibitor of the activator of nuclear factor kappa B kinase (IKK-gamma), which is in Phase 2 clinical development for the treatment of ulcerative colitis and Crohn’s disease. Landos Biopharma Inc has a market cap of 12.72M as of 2022. The company has a Return on Equity of -64.92%.

    – PDS Biotechnology Corp ($NASDAQ:PDSB)

    PDS Biotechnology Corporation is a clinical-stage immuno-oncology company, which engages in the development of therapeutic and preventive products based on its proprietary Versamune T-cell activation platform. The company’s products are used in the treatment of various solid tumors, hematologic malignancies, and infectious diseases. PDS Biotechnology Corporation was founded by Pritesh H. Shah, Erle T. H. Melber, and Robert L. Dillman in 2007 and is headquartered in Princeton, NJ.


    XENCOR saw an impressive growth in revenue for Q2 of FY2023, with a 50.8% increase from the same quarter the year before. Despite a net income loss of USD -22.0 million, this was still an improvement from the previous year of -34.0 million. Investors will be attracted to XENCOR’s strong revenue growth and are likely to view the company favorably due to the decreasing net income losses. It will be important for investors to monitor XENCOR’s performance in the following quarters to ensure continued positive financial results.

    Recent Posts

    Leave a Comment